NCT00245245View on ClinicalTrials.gov

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2005

Study Completion Date

June 30, 2007

Conditions
Hemophilia A
Interventions
DRUG

recombinant porcine coagulation factor VIII (OBI-1)

Trial Locations (1)

19422

Octagen Corporation, Blue Bell

Sponsors
All Listed Sponsors
collaborator

Biomeasure Inc, Ipsen Group

INDUSTRY

lead

Octagen Corporation

INDUSTRY

NCT00245245 - Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII | Biotech Hunter | Biotech Hunter